Literature DB >> 26515334

Letter regarding "CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis" by Zhang et al.

Shing Cheng Tan1.   

Abstract

Entities:  

Keywords:  FAS; Genetic variation; Meta-analysis; Risk; Uterine cervical neoplasms

Mesh：

Substances：

Year:  2015        PMID： 26515334     DOI： 10.1007/s13277-015-4330-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


× No keyword cloud information.
  5 in total

1.  Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis.

Authors:  Jian Shen; Ning-Xia Sun
Journal:  Tumour Biol       Date:  2013-07-31

2.  CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.

Authors:  Yan Zhang; Shengchun Tong; Lihua Guan; Fei Na; Wei Zhao; Li Wei
Journal:  Tumour Biol       Date:  2013-10-11

3.  Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease.

Authors:  M Zoodsma; I M Nolte; M Schipper; E Oosterom; G van der Steege; E G E de Vries; G J Te Meerman; A G J van der Zee
Journal:  Int J Gynecol Cancer       Date:  2005 Nov-Dec       Impact factor: 3.437

4.  Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis.

Authors:  Hung-Cheng Lai; Huey-Kang Sytwu; Chien-An Sun; Mu-Hsien Yu; Cheng-Ping Yu; Hang-Seng Liu; Cheng-Chang Chang; Tang-Yuan Chu
Journal:  Int J Cancer       Date:  2003-01-10       Impact factor: 7.396

5.  Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans.

Authors:  Koushik Chatterjee; Malin Engelmark; Ulf Gyllensten; Collet Dandara; Lize van der Merwe; Ushma Galal; Margaret Hoffman; Anna-Lise Williamson
Journal:  BMC Res Notes       Date:  2009-11-26
  5 in total
  1 in total

1.  Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females.

Authors:  Meng Wang; Zheng Wang; Xi-Jing Wang; Tian-Bo Jin; Zhi-Ming Dai; Hua-Feng Kang; Hai-Tao Guan; Xiao-Bin Ma; Xing-Han Liu; Zhi-Jun Dai
Journal:  Drug Des Devel Ther       Date:  2016-07-25       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.